Robert LeBoyer

Stock Analyst at Noble Capital Markets

(1.20)
# 3,763
Out of 5,242 analysts
18
Total ratings
31.25%
Success rate
-0.26%
Average return

Stocks Rated by Robert LeBoyer

Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $14.00
Upside: +400.00%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $3.49
Upside: +272.49%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $150$250
Current: $2.75
Upside: +8,990.91%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $7.63
Upside: +686.37%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $5.17
Upside: +1,060.54%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $3.89
Upside: +157.07%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.28
Upside: +993.75%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.32
Upside: +506.06%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $3,000
Current: $6.89
Upside: +43,441.36%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $11.40
Upside: -
Initiates: Buy
Price Target: $12
Current: $2.71
Upside: +342.80%
Initiates: Buy
Price Target: $9,900,000
Current: $5.05
Upside: +196,039,503.96%
Downgrades: Neutral
Price Target: n/a
Current: $34.72
Upside: -
Initiates: Buy
Price Target: $15
Current: $2.30
Upside: +552.17%